Medicare Enrolled
Dr. Jeffrey Sugarman, M.D., PH.D.
Pediatric Dermatology Physician · Santa Rosa, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Sugarman from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Sugarman?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Sugarman
Dr. Jeffrey Sugarman is a pediatric dermatology physician in Santa Rosa, CA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Sugarman performed 13,043 Medicare services across 4,222 unique beneficiaries.
Between the years covered by Open Payments, Dr. Sugarman received a total of $440,831 from 36 pharmaceutical and/or device companies across 818 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pediatric dermatology physician. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Sugarman is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 14% volume in CA
$440,831 industry payments
Medicare Practice Summary
Medicare Utilization ↗13,043
Medicare services
Top 14% in CA for pediatric dermatology physician
4,222
Unique beneficiaries
$34
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~652 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Tissue pathology examination, moderate complexity A laboratory test where a pathologist examines tissue samples under a microscope to analyze cellular details. This intermediate complexity procedure involves specialized techniques to identify abnormalities in the tissue. |
10,252 | $32 | $95 |
| Destruction of precancerous skin growths, 2-14 This procedure involves the removal or destruction of two to fourteen precancerous skin lesions. It is performed to eliminate abnormal skin cells that have the potential to develop into cancer. |
824 | $5 | $17 |
| Ultraviolet light skin treatment Application of ultraviolet light to the skin for therapeutic purposes. |
399 | $21 | $55 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
309 | $60 | $160 |
| Pathology tissue examination, moderate complexity A laboratory test where a pathologist examines tissue samples under a microscope to identify abnormalities. This specific level indicates a moderate degree of complexity in the analysis. |
250 | $20 | $53 |
| Destruction of precancerous skin growth, 1 Removal of a single precancerous skin growth. This procedure destroys abnormal skin cells to prevent them from developing into cancer. |
203 | $40 | $130 |
| Skin biopsy, tangential A procedure to remove a sample of the first identified skin growth for laboratory examination. |
136 | $73 | $220 |
| UV therapy with tar or petroleum jelly A treatment using ultraviolet radiation combined with the application of tar or petroleum jelly to the skin. |
113 | $103 | $155 |
| Destruction of 15 or more precancerous skin growths This procedure involves the removal or destruction of fifteen or more precancerous skin lesions. It is performed to treat abnormal skin cells that have the potential to develop into cancer. |
100 | $136 | $270 |
| Special tissue stain and interpretation A laboratory test using special stains to examine tissue samples, including the pathologist's review and written report of the findings. |
63 | $43 | $107 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
62 | $37 | $92 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
61 | $10 | $50 |
| Destruction of skin growths (warts/lesions), 1-14 This procedure involves the removal or destruction of one to fourteen skin growths. It is a minor surgical intervention performed on the skin surface. |
49 | $78 | $235 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
42 | $91 | $225 |
| Additional skin growth biopsy Removal of a sample of an additional skin growth for laboratory examination. This code is used for each extra lesion biopsied during the same session. |
39 | $43 | $120 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
39 | $67 | $225 |
| Topical aminolevulinic acid HCl 20% solution A topical medication applied to the skin for medical treatment. It is supplied as a single-unit dosage form containing 354 mg of the active ingredient. |
27 | $302 | $700 |
| New patient office visit, 15-29 minutes An initial office visit for a new patient lasting 15 to 29 minutes. This code is used when the total time spent on the date of the encounter meets this duration threshold. |
26 | $43 | $155 |
| Light therapy to destroy precancerous skin growth This procedure uses light to treat and remove precancerous skin lesions. It is a method for destroying abnormal skin cells before they become cancerous. |
23 | $113 | $300 |
| Surgical removal of skin cancer, 1.1-2.0 cm Surgical excision of a cancerous skin growth measuring between 1.1 and 2.0 centimeters on the body, arms, or legs. |
13 | $117 | $525 |
| Intermediate wound repair, 2.6-7.5 cm A medical procedure to close a wound on the scalp, underarms, trunk, arms, or legs that measures between 2.6 and 7.5 centimeters. This type of repair involves cleaning the wound and stitching it closed to promote healing. |
13 | $229 | $645 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$440,831
Total received (2018-2024)
Avg $62,976/year across 7 years
Top 4% in CA for pediatric dermatology physician
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
36
Companies
818
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$298,816 (67.8%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$134,760 (30.6%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$7,255 (1.6%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$104,534
2023
$100,858
2022
$24,677
2021
$30,970
2020
$34,030
2019
$90,664
2018
$55,099
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Regeneron Healthcare Solutions, Inc.
$33,315
Incyte Corporation
$21,569
ABBVIE INC.
$19,404
Evolved By Nature, Inc.
$8,000
PFIZER INC.
$7,600
GENZYME CORPORATION
$4,802
Arcutis Biotherapeutics, Inc.
$2,439
LNHC, Inc
$2,349
Boehringer Ingelheim Pharmaceuticals, Inc.
$2,348
Dermavant Sciences, Inc.
$1,060
NOBELPHARMA AMERICA, LLC
$400
E.R. Squibb & Sons, L.L.C.
$245
Novartis Pharmaceuticals Corporation
$245
Janssen Biotech, Inc.
$234
Lilly USA, LLC
$220
UCB, Inc.
$96
Amgen Inc.
$62
Almirall LLC
$49
Genentech USA, Inc.
$22
Galderma Laboratories, L.P.
$20
Ortho Dermatologics, a division of Bausch Health US, LLC
$20
Organon Llc
$17
LEO Pharma Inc.
$16
Top 3 companies account for 71.1% of 2024 payments
All-time payments by company (2018-2024) ›
Regeneron Healthcare Solutions, Inc.
$164,115
GENZYME CORPORATION
$72,675
PFIZER INC.
$63,544
Incyte Corporation
$53,546
ABBVIE INC.
$19,959
Ortho Dermatologics, a division of Bausch Health US, LLC
$19,412
Regeneron Pharmaceuticals, Inc.
$10,189
E.R. Squibb & Sons, L.L.C.
$8,727
Evolved By Nature, Inc.
$8,000
Novartis Pharmaceuticals Corporation
$5,424
Arcutis Biotherapeutics, Inc.
$4,417
Boehringer Ingelheim Pharmaceuticals, Inc.
$2,374
LNHC, Inc
$2,349
AbbVie Inc.
$1,406
Dermavant Sciences, Inc.
$1,096
Lilly USA, LLC
$598
Janssen Biotech, Inc.
$560
NOBELPHARMA AMERICA, LLC
$400
Amgen Inc.
$378
Allergan, Inc.
$260
Sun Pharmaceutical Industries Inc.
$257
Galderma Laboratories, L.P.
$214
AbbVie, Inc.
$201
UCB, Inc.
$132
Pierre Fabre Pharmaceuticals, Inc.
$124
Genentech USA, Inc.
$93
LEO Pharma Inc.
$90
Biofrontera Inc.
$59
Almirall LLC
$49
Akcea Therapeutics, Inc.
$47
Bausch Health US, LLC
$45
Kyowa Kirin, Inc.
$23
Fresenius Kabi USA, LLC
$23
Medtronic Vascular, Inc.
$17
Organon Llc
$17
STRATA Skin Sciences, Inc.
$11
Top 3 companies account for 68.1% of all-time payments
Associated products mentioned in payments ›
ADBRY · ALTRENO · AMELUZ · Ameluz · BOTOX · Bimzelx · CIBINQO · COSENTYX · Cimzia · DUOBRII · DUPIXENT · DUPIXENT DUPILUMAB INJECTION · Dermatological Psoriasis and Vitiligo Treatment · ENSTILAR · EUCRISA · Erivedge · FINACEA · HADLIMA · HEMANGEOL · HUMIRA · HYFTOR · Humira · IDACIO · ILUMYA · ILUMYA (tildrakizumab-asmn) injection · LIBTAYO · OPZELURA · ORACEA · Otezla · Poteligeo · REMICADE · RINVOQ · SILIQ · SKYRIZI · SPEVIGO · Seysara · Skyrizi · Sotyktu · TALTZ · TEGSEDI · TREMFYA · Tremfya · VTAMA · VenaSeal · Winlevi · XELJANZ · XOLAIR · Xolair · Zoryve
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (68%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in pediatric dermatology physician and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 4% for pediatric dermatology physician in CA.
Geographic Context
Pediatric dermatology physicians within 10 mi
1
Per 100K population
0.2
County median income
$102,840
Nearest hospital
SUTTER SANTA ROSA REGIONAL HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Sugarman is a mixed practice specialist, with above-average Medicare volume (top 14% in CA), with speaking/promotional industry engagement in the top 4% of CA peers, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Sugarman experienced with tissue pathology examination, moderate complexity?
Based on Medicare claims data, Dr. Sugarman performed 10,252 tissue pathology examination, moderate complexity services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Sugarman receive payments from pharmaceutical companies?
Yes. Dr. Sugarman received a total of $440,831 from 36 companies across 818 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Sugarman's costs compare to other pediatric dermatology physicians in Santa Rosa?
Dr. Sugarman's average Medicare payment per service is $34. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Sugarman) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Pediatric Dermatology Physicians in Santa Rosa
Browse pediatric dermatology physicians in Santa Rosa ranked by procedure volume and transparency data.
Highest volume
Top Pediatric Dermatology Physicians in CA
Pediatric dermatology physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pediatric Dermatology Physicians in CA
Which CA pediatric dermatology physicians receive the most from drug and device companies.
By company
Regeneron Healthcare Solutions, Inc. Payments to Doctors
See all physicians who received payments from Regeneron Healthcare Solutions, Inc.
By company
GENZYME CORPORATION Payments to Doctors
See all physicians who received payments from GENZYME CORPORATION.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology